首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1671863

重組疫苗市場按類型、適應症、最終用戶、分銷管道和地區分類

Recombinant Vaccine Market, By Type, By Indication, By End User, By Distribution Channel, By Geography

出版日期: 2025年02月26日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球重組疫苗市場規模估計為 125.2 億美元，預計到 2032 年將達到 271.7 億美元，2025 年至 2032 年的複合年成長率為 11.7%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	125.2億美元
效能資料	從 2020 年到 2024 年	預測期	2025 至 2032 年
預測期：2025-2032年複合年成長率：	11.70％	2032 年價值預測	271.7億美元

數字。 2025 年重組疫苗市場佔有率（按地區分類）

重組疫苗是利用重組 DNA 技術開發而成，將編碼疫苗抗原的基因與其他生物（例如酵母菌、細菌或病毒）的基因結合。將重組基因引入宿主細胞，然後在大型發酵槽中培養以產生抗原蛋白。重組技術克服了傳統疫苗生產的許多限制，它可以在精確控制的條件下大量生產抗原，而不受季節或疾病爆發的影響。由於生產成本低、產量高、可擴展等優勢，全球重組疫苗市場預計將在預測期內顯著成長。

市場動態：

由於感染疾病流行的增加、疫苗接種意識的增強以及重組 DNA 生產技術的進步等因素，全球重組疫苗市場預計將實現強勁成長。然而，高昂的開發成本和嚴格的法律規範預計會阻礙市場成長。同時，擁有大量未開發人口的新興國家也為製造商提供了豐厚的商機。市場開發商正在投資研發新疾病適應症的疫苗和聯合疫苗，以便在檢查時提供加強劑量的機會，從而提高患者的依從性。

本研究的主要特點

本報告對全球重組疫苗市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。

它還強調了各個領域的潛在商機並解釋了該市場的有吸引力的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

全球重組疫苗市場的主要企業是根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行的分析。

主要企業包括默克公司、賽諾菲公司、輝瑞公司、葛蘭素史克公司、強生公司、諾瓦瓦克斯公司、阿斯特捷利康公司、Dynavax Technologies Corporation、印度血清研究所。 Ltd.、Emergent BioSolutions Inc.、Bharat Biotech、Protein Sciences Corporation、VBI Vaccines Inc. 和 Inovio Pharmaceuticals, Inc.

本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。

全球重組疫苗市場報告迎合了該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員將透過用於分析全球重組疫苗市場的各種策略矩陣來做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	US$ 12.52 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	11.70%	2032 Value Projection:	US$ 27.17 Bn

Recombinant vaccines are developed using recombinant DNA technology by combining genes that code for vaccine antigens with the genes of another organism like yeast, bacteria, or viruses. The recombinant genes are then transferred into host cells which are then cultured in large fermenters to produce antigen proteins. Recombinant technology overcomes many limitations of conventional vaccine production as antigens can be mass produced in precisely controlled conditions regardless of season or disease outbreak. With benefits of low production cost, high yield and scalability, the global recombinant vaccine market is expected to experience significant growth over the forecast period.

Market Dynamics:

The global recombinant vaccine market is projected to witness robust growth attributable to factors such as increasing prevalence of infectious diseases, rising awareness about vaccination, and technological advancement in recombinant DNA production techniques. However, high development costs and stringent regulatory framework are expected to impede the market growth. On the other hand, emerging economies with large untapped populations present lucrative opportunities for manufacturers. Market players are investing in R&D to develop vaccines for new disease indications as well as combination vaccines which provide an opportunity for additional vaccination during well-child visits, thereby improving patient compliance.

Key Features of the Study:

This report provides in-depth analysis of the global recombinant vaccine market and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global recombinant vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Merck & Co., Inc., Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson, Novavax, Inc., AstraZeneca Plc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Emergent BioSolutions Inc., Bharat Biotech, Protein Sciences Corporation, VBI Vaccines Inc., and Inovio Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global recombinant vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant vaccine market

Market Segmentation

By Type Insights (Revenue, USD Bn, 2020 - 2032)
- Attenuated Recombinant Vaccines
- Vector Recombinant Vaccines
- Subunit Recombinant Vaccines
By Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Human Papillomavirus (HPV)
- Meningococcal
- Hepatitis B
- Influenza
- Rotavirus
- Herpes Zoster
- Others
By End User Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital & Retail Pharmacies
- Government Suppliers
- Vaccination Centers
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Merck & Co., Inc.
- Sanofi S.A.
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Novavax, Inc.
- AstraZeneca Plc.
- Dynavax Technologies Corporation
- Serum Institute of India Pvt. Ltd.
- Emergent BioSolutions Inc.
- Bharat Biotech
- Protein Sciences Corporation
- VBI Vaccines Inc.
- Inovio Pharmaceuticals, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Recombinant Vaccine Market, By Type
- Global Recombinant Vaccine Market, By Indication
- Global Recombinant Vaccine Market, By End User
- Global Recombinant Vaccine Market, By Distribution Channel
- Global Recombinant Vaccine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Recombinant Vaccine Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Attenuated Recombinant Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Vector Recombinant Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subunit Recombinant Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Recombinant Vaccine Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Human Papillomavirus (HPV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Meningococcal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hepatitis B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Influenza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rotavirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Herpes Zoster
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Recombinant Vaccine Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Recombinant Vaccine Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital & Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Government Suppliers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Vaccination Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Recombinant Vaccine Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline Plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novavax, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Dynavax Technologies Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Emergent BioSolutions Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Protein Sciences Corporation
VBI Vaccines Inc.
Inovio Pharmaceuticals, Inc.